Baixar PDF

Outros usuários também visualizaram estes artigos

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY A. Maiolino; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;
Hematol Transfus Cell Ther. 2020;42 Supl 2:262-3
POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS M. Dimopoulos; K. Weisel; P. Moreau; L.D.A. Jr; D. White; J.S. Miguel; P. Sonneveld; M. Engelhardt; M. Jenner; A. Corso; J. Dürig; M. Pavic; M. Salomo; E. Casal; R. Jiang; T. Nguyen; T. Peluso; P. Richardson;
Hematol Transfus Cell Ther. 2020;42 Supl 2:272-3
BRAZILIAN REAL-WORLD MULTIPLE MYELOMA (MM) ELECTRONIC PLATFORM REGISTER PROJECT E.Q. Crusoé; G. Ribeiro; K.R. Zanella; L.M. Perobelli; M.A.F. Aranha; M.E.Z. Capra; R.J.P. Magalhaes; J.F. Maciel; A. Maiolino; V.T. Hungria;
Hematol Transfus Cell Ther. 2020;42 Supl 2:253